BIOPARTNER APPOINTS TWO NEW ADVISORY BOARD MEMBERS

Dr Rachel Hemsley is the global head of business development at Nottingham based XenoGesis, the contract research organisation (CRO) specialising in DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation. Rachel is responsible for identifying and managing a portfolio of potential and new clients and building strong relationships with external companies. She was previously the Senior Business Manager at UCL Business plc and brings to the Board 12 years’ experience in business development involving early stage technology development, securing investment funding, licensing early stage healthcare technology and setting up new companies.

Paul Cronin is a Director at Clinical Network Services (UK), an integrated service group focused on product development, and has overall responsibility for its day to day operations. With over 15 years’ experience in the pharmaceutical industry, he has held senior positions at a variety of regulatory/product development consultancies and clinical CROs. Paul has degrees in biochemistry and international business and management and started his pharmaceutical career as a Regulatory Affairs Consultant. He has been responsible for growing global business activities and evolving the CNS business into a leading international group.

BioPartner works closely with UK bioscience sector stakeholders including regional networks, national trade associations, and government departments; to promote UK expertise and to provide cost-effective access to overseas partners and new markets for UK-based organisations. Rachel and Paul join Alasdair Stamps, Will Watson, Dave Mead, and Hakan Goker, We welcome nominations from similarly experienced people.